Gilead Buys Out Remaining Rights to Jounce Immunotherapy Candidate

Gilead Sciences is acquiring all rights to Jounce Therapeutics immunotherapy candidate GS-1811 — formerly known as JTX-1811 — for treatment of solid tumors.

In early-stage studies, GS-1811 is showing promise in selectively depleting immunosuppressive cells in the tumors.

The two companies inked an initial licensing deal in 2020, including an upfront payment by Gilead of $85 million and a $35 million equity investment in Jounce.

With the updated agreement, Jounce will receive an additional $67 million but will no longer be eligible for future milestone payments.